Zobrazeno 1 - 10 of 332 pro vyhledávání: '"D, Eleftheriou"'
1
Akademický článek
Systemic juvenile idiopathic arthritis: The Great Ormond Street Hospital experience (2005–2021)
Autor: C. M. Foley, D. McKenna, K. Gallagher, K. McLellan, H. Alkhdher, S. Lacassagne, E. Moraitis, C. Papadopoulou, C. Pilkington, M. Al Obaidi, D. Eleftheriou, P. Brogan
Publikováno v: Frontiers in Pediatrics, Vol 11 (2023)
Systemic juvenile idiopathic arthritis (sJIA) is a complex, systemic inflammatory disorder driven by both innate and adaptive immunity. Improved understanding of sJIA pathophysiology has led to recent therapeutic advances including a growing evidence
Externí odkaz: https://doaj.org/article/2df2dc3ea9f24bce82c13d7bc7db26d6
Zobrazit plný text záznamu
3
Spectrum of Neuroradiologic Findings Associated with Monogenic Interferonopathies
Autor: P. Benjamin, S. Sudhakar, F. D’Arco, U. Löbel, O. Carney, C.-J. Roux, N. Boddaert, C. Hemingway, D. Eleftheriou, K. Mankad
Publikováno v: AJNR Am J Neuroradiol
The genetic interferonopathies are a heterogeneous group of disorders thought to be caused by the dysregulated expression of interferons and are now commonly considered in the differential diagnosis of children presenting with recurrent or persistent
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72bbfaf2057d622e70b38e008b99773b
https://europepmc.org/articles/PMC8757560/
Zobrazit plný text záznamu
4
Akademický článek
Pulmonary fibrosis presenting as an early manifestation of microscopic polyangiitis
Autor: D. Eleftheriou, S. Katsenos, S. Zorbas, I. Griveas, K. Psathakis
Publikováno v: Monaldi Archives for Chest Disease, Vol 77, Iss 3-4 (2015)
Microscopic polyangiitis (MPA) is a systemic small vessel vasculitis that is included in the pulmonary-renal syndromes. Although glomerulonephritis represents the major clinical feature of MPA indicative of renal involvement, diffuse alveolar haemorr
Externí odkaz: https://doaj.org/article/0ed1020c4b744fbdaa258138b09b894c
Zobrazit plný text záznamu
8
AB1236 CLINICAL CHARACTERISTICS OF JUVENILE ONSET SYSTEMIC SCLEROSIS PATIENTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT COMPARED TO ADULT AGE JUVENILE-ONSET PATIENTS FROM EUSTAR. ARE THESE DIFFERENCES SUGGESTING RISK FOR MORTALITY?
Autor: I. Foeldvari, J. Klotsche, P. Carreira, O. Kasapcopur, K. Torok, P. Airò, F. Iannone, Y. Allanore, A. Balbir-Gurman, T. Schmeiser, F. R. Sztajnbok, M. T. Terreri, V. Stanevicha, J. Anton, B. Feldman, R. Khubchandani, E. Alexeeva, S. Johnson, M. Katsikas, S. Sawhney, V. Smith, S. Appenzeller, T. Avcin, C. Campochiaro, J. De Vries-Bouwstra, M. Kostik, T. Lehman, E. Marrani, D. Schonenberg, W. A. Sifuentes-Giraldo, N. Vasquez-Canizares, M. Janarthanan, H. Malcova, M. Moll, D. Nemcova, A. Patwardhan, M. J. Santos, G. Seskute, M. E. Truchetet, C. Battagliotti, L. Berntson, B. Bica, J. Brunner, R. Cimaz, P. Costa Reis, D. Eleftheriou, L. Harel, G. Horneff, D. Kaiser, T. Kallinich, D. Lazarevic, K. Minden, S. Nielsen, F. Nuruzzaman, S. Opsahl Hetlevik, Y. Uziel, D. Veale, A. M. Hoffmann-Vold, A. Gabrielli, O. Distler
Publikováno v: Annals of the Rheumatic Diseases. 81:1729.2-1730
BackgroundJuvenile systemic sclerosis (jSSc) is an orphan autoimmune disease with a prevalence of 3 in 1 000 000 children. Information on long-term development of organ involvement and clinical characteristics of jSSc patients in adulthood are lackin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2079b50ebe8989bcc6b344d73eddbc99
https://doi.org/10.1136/annrheumdis-2022-eular.1531
Zobrazit plný text záznamu
9
OP0193 EFFICACY AND SAFETY OF EMAPALUMAB, AN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WHO HAD FAILED HIGH-DOSE GLUCOCORTICOIDS
Autor: F. De Benedetti, A. Grom, P. Brogan, C. Bracaglia, M. Pardeo, G. Marucci, D. Eleftheriou, C. Papadopoulou, P. Quartier, J. Anton, R. Frederiksen, V. Asnaghi, C. de Min
Publikováno v: Annals of the Rheumatic Diseases. 81:128.2-128
BackgroundMAS is a severe, life-threatening complication of rheumatic diseases that occurs most frequently in patients with sJIA. The mainstay of treatment for MAS is high dose glucocorticoids (GCs); however, GCs do not provide adequate control in al
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d38ef2818c1b798e55a9ba9b84611cbb
https://doi.org/10.1136/annrheumdis-2022-eular.803
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje